Under Development
PRIAS (Prostate cancer Research International: Active Surveillance) presents a program in which selected men with early prostate cancer are managed by a protocolized follow-up strategy. Candidates for this program are: men fit for curative therapy, PSA at diagnosis less than 10 ng/mL, PSA density (PSA/prostatic volume) less than 0.20, one or two biopsy cores bearing prostate cancer (using a fixed volume-dependent number of cores), Gleason score 3+3 and digital rectal examination T1c or T2.